Compare LODE & MIST Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LODE | MIST |
|---|---|---|
| Founded | 1999 | 2003 |
| Country | United States | Canada |
| Employees | 45 | N/A |
| Industry | Major Chemicals | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 171.0M | 146.9M |
| IPO Year | 2004 | 2019 |
| Metric | LODE | MIST |
|---|---|---|
| Price | $2.27 | $0.82 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $5.86 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 10-29-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 63.55 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,553,796.00 | N/A |
| Revenue This Year | $303.79 | $147.62 |
| Revenue Next Year | $410.04 | $476.43 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.23 | $0.75 |
| 52 Week High | $4.98 | $3.06 |
| Indicator | LODE | MIST |
|---|---|---|
| Relative Strength Index (RSI) | 27.65 | 40.29 |
| Support Level | N/A | N/A |
| Resistance Level | $3.61 | $1.42 |
| Average True Range (ATR) | 0.17 | 0.06 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 17.21 | 46.38 |
Comstock Inc commercializes technologies that convert underutilized waste and natural resources into clean energy and supporting products, including electrification, metals, and minerals from end-of-life solar panels. Its subsidiary focuses on producing renewable fuels from waste, energy crops, and woody biomass, supported by facilities in Wisconsin, pilot farms, a biorefinery site in Tulsa, and solar panel recycling operations in Nevada. The Company operates through two high-growth segments and a corporate segment, with its activities grouped into Metals, which generates the majority of revenue, Fuels, Mining, Strategic Investments, and Corporate Services.
Milestone Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of cardiovascular medicines. Its approved product CARDAMYST (etripamil) nasal spray is available in the United States and is the self-administered treatment for use by patients anywhere, anytime an attack of PSVT occurs. It operates in single segment.